FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) Meeting FDA White Oak Campus, Building 31, The Great Room (Rm. 1503) - Familial amyloid cardiomyopathy - Document - PDFSEARCH.IO

First Page	Meta Content
	FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) Meeting FDA White Oak Campus, Building 31, The Great Room (Rm. 1503) Add to Reading List Open Document File Size: 35,72 KB Share Result on Facebook Company Pfizer Inc. / FoldRx Pharmaceuticals Inc. / / Facility Meeting FDA White Oak Campus / White Oak Conference Center / / MedicalCondition Transthyretin Amyloid Polyneuropathy / familial amyloid polyneuropathy / / Organization Peripheral and Central Nervous System Drugs Advisory Committee / Division of Neurology Products / Center for Drug Evaluation and Research / office of New Drugs / FOOD AND DRUG ADMINISTRATION / / Person Introductory Remarks Russell Katz / Nathan B. Fountain / Glendolynn S. Johnson / / Position Federal Officer / Director / Chair / / SocialTag Neurology Tafamidis Transthyretin-related hereditary amyloidosis Food and Drug Administration Transthyretin Familial amyloid neuropathy Polyneuropathy Center for Drug Evaluation and Research Familial amyloid cardiomyopathy Neurological disorders

FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) Meeting FDA White Oak Campus, Building 31, The Great Room (Rm. 1503)Add to Reading List